Catalent Pharma Solutions, a leading provider of outsourced dose form manufacturing and packaging to the global pharmaceutical industry, recently announced it has expanded its capabilities in its Schorndorf, Germany, site to include a new potent products area. This important new capability enables Catalent to provide customers with complex and innovative dose form production, over-encapsulation, and packaging solutions for potent products at its Schorndorf site.

For nearly 50 years, Catalent’s Schorndorf operation has provided a broad range of services to global, regional, and local pharmaceutical customers. Today, Catalent provides oral dose form development, manufacturing, and packaging services, as well as comprehensive supply chain solutions. In the fall of 2009, Catalent’s Schorndorf facility successfully completed an FDA inspection adding to a long track-record of regulatory compliance, including German and other EU and international regulatory authorities.

“We believe the addition of this new potent handling and over-encapsulation area will help to meet the needs of our customers, both global and local. I am also pleased that this investment was made here in Schorndorf, as it builds upon our team’s commitment to operational excellence, our regulatory track-record, and our consistent focus on meeting our customers’ needs,” said Eric Schmidhaeuser, Managing Director of the Schorndorf operation.

Headquartered in Somerset, NJ, Catalent is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging, and printing services for pharmaceutical, biotechnology, and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets, and enhance patient outcomes. Catalent employs approximately 9,400 at 30 facilities worldwide and in fiscal 2009 generated more than $1.6 billion of annual revenue.